The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2026 | PERSEE: Pembrolizumab ± chemotherapy in PD-L1 high advanced NSCLC
Chantal Decroisette, MD, Centre Léon-Bérard, Lyon, France, discusses results from the Phase III PERSEE trial (GFPC 01-2020; EudraCT 2020-002626-86), which compared first-line pembrolizumab plus platinum-based chemotherapy with pembrolizumab alone in advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression. Adding chemotherapy significantly improved progression-free survival and response rates, with a favorable but non-significant trend in overall survival. Higher rates of severe treatment-related adverse events were seen with the combination. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
